153 related articles for article (PubMed ID: 20157061)
1. Oncolysis using herpes simplex virus type 1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma.
Price DL; Lin SF; Han Z; Simpson G; Coffin RS; Wong J; Li S; Fong Y; Wong RJ
Arch Otolaryngol Head Neck Surg; 2010 Feb; 136(2):151-8. PubMed ID: 20157061
[TBL] [Abstract][Full Text] [Related]
2. Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer.
Simpson GR; Horvath A; Annels NE; Pencavel T; Metcalf S; Seth R; Peschard P; Price T; Coffin RS; Mostafid H; Melcher AA; Harrington KJ; Pandha HS
Br J Cancer; 2012 Jan; 106(3):496-507. PubMed ID: 22240799
[TBL] [Abstract][Full Text] [Related]
3. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
Simpson GR; Han Z; Liu B; Wang Y; Campbell G; Coffin RS
Cancer Res; 2006 May; 66(9):4835-42. PubMed ID: 16651439
[TBL] [Abstract][Full Text] [Related]
4. Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus.
Zaoui K; Bossow S; Grossardt C; Leber MF; Springfeld C; Plinkert PK; Kalle Cv; Ungerechts G
Cancer Gene Ther; 2012 Mar; 19(3):181-91. PubMed ID: 22076043
[TBL] [Abstract][Full Text] [Related]
5. Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model.
Chen SH; Sun JM; Chen BM; Lin SC; Chang HF; Collins S; Chang D; Wu SF; Lu YC; Wang W; Chen TC; Kasahara N; Wang HE; Tai CK
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093290
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Efficacy of Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors for Human Ovarian Cancer.
Isoda L; Sonoda-Fukuda E; Fujino H; Takarada T; Hasegawa K; Kasahara N; Kubo S
Anticancer Res; 2023 Dec; 43(12):5311-5317. PubMed ID: 38030176
[TBL] [Abstract][Full Text] [Related]
7. Highly efficient tumor transduction and antitumor efficacy in experimental human malignant mesothelioma using replicating gibbon ape leukemia virus.
Kubo S; Takagi-Kimura M; Logg CR; Kasahara N
Cancer Gene Ther; 2013 Dec; 20(12):671-7. PubMed ID: 24201868
[TBL] [Abstract][Full Text] [Related]
8. Replicating retroviral vectors for oncolytic virotherapy of experimental hepatocellular carcinoma.
Lu YC; Chen YJ; Yu YR; Lai YH; Cheng JC; Li YF; Shen CH; Tai CK
Oncol Rep; 2012 Jul; 28(1):21-6. PubMed ID: 22552490
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation.
Yamada S; Kuroda T; Fuchs BC; He X; Supko JG; Schmitt A; McGinn CM; Lanuti M; Tanabe KK
Cancer Gene Ther; 2012 Mar; 19(3):160-70. PubMed ID: 22076044
[TBL] [Abstract][Full Text] [Related]
10. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil.
Nakamura H; Mullen JT; Chandrasekhar S; Pawlik TM; Yoon SS; Tanabe KK
Cancer Res; 2001 Jul; 61(14):5447-52. PubMed ID: 11454690
[TBL] [Abstract][Full Text] [Related]
11. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus.
Wong RJ; Kim SH; Joe JK; Shah JP; Johnson PA; Fong Y
J Am Coll Surg; 2001 Jul; 193(1):12-21. PubMed ID: 11442249
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy of lung adenocarcinoma using herpes virus expressing a fusogenic membrane glycoprotein.
Zhu B; Yang JR; Jiang YQ; Chen SF; Fu XP
Cell Biochem Biophys; 2014 Jul; 69(3):583-7. PubMed ID: 24510538
[TBL] [Abstract][Full Text] [Related]
13. Retroviral Replicating Vectors Mediated Prodrug Activator Gene Therapy in a Gastric Cancer Model.
Fujino H; Sonoda-Fukuda E; Isoda L; Kawabe A; Takarada T; Kasahara N; Kubo S
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834271
[TBL] [Abstract][Full Text] [Related]
14. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase.
Hamstra DA; Rice DJ; Fahmy S; Ross BD; Rehemtulla A
Hum Gene Ther; 1999 Aug; 10(12):1993-2003. PubMed ID: 10466633
[TBL] [Abstract][Full Text] [Related]
15. Combined radiation and enzyme/prodrug treatment for head and neck cancer in an orthotopic animal model.
Hamstra DA; Rice DJ; Pu A; Oyedijo D; Ross BD; Rehemtulla A
Radiat Res; 1999 Nov; 152(5):499-507. PubMed ID: 10521927
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer.
Li P; Chen CH; Li S; Givi B; Yu Z; Zamarin D; Palese P; Fong Y; Wong RJ
Head Neck; 2011 Oct; 33(10):1394-9. PubMed ID: 21928411
[TBL] [Abstract][Full Text] [Related]
17. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect.
Fu X; Tao L; Jin A; Vile R; Brenner MK; Zhang X
Mol Ther; 2003 Jun; 7(6):748-54. PubMed ID: 12788648
[TBL] [Abstract][Full Text] [Related]
18. Efficient tumor transduction and antitumor efficacy in experimental human osteosarcoma using retroviral replicating vectors.
Kubo S; Takagi-Kimura M; Kasahara N
Cancer Gene Ther; 2019 Feb; 26(1-2):41-47. PubMed ID: 30042500
[TBL] [Abstract][Full Text] [Related]
19. 5-Fluorocytosine increases the toxicity of Wnt-targeting replicating adenoviruses that express cytosine deaminase as a late gene.
Fuerer C; Iggo R
Gene Ther; 2004 Jan; 11(2):142-51. PubMed ID: 14712298
[TBL] [Abstract][Full Text] [Related]
20. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck.
Kim SH; Wong RJ; Kooby DA; Carew JF; Adusumilli PS; Patel SG; Shah JP; Fong Y
Eur J Cancer; 2005 Jan; 41(2):313-22. PubMed ID: 15661558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
